16:41 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million on June 6 in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and...
15:22 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
19:48 , Jun 6, 2018 |  BC Extra  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and Vivo Capital also...
14:09 , Jun 4, 2018 |  BC Extra  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM reports Phase II data for NGM282 in primary sclerosing cholangitis

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported additional data from a Phase II trial in 62 primary sclerosing cholangitis (PSC) patients with elevated alkaline phosphatase levels showing that once-daily subcutaneous 3 mg NGM282 significantly...
19:32 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM's NGM282 meets in Phase II data for NASH

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported data from a single-blind Phase II trial in 19 non-alcoholic steatohepatitis (NASH) patients showing that once-daily subcutaneous 3 mg NGM282 met the primary endpoint of reducing absolute...
03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other molecule...
16:02 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample and mouse studies suggest inhibiting the IL-6-JAK-STAT3 axis could help treat FGF19-driven hepatocellular cancer (HCC). In HCC patients, high tumor levels of FGF19 were associated with poor overall survival and...
21:05 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

NGM282: Additional Ph II data

Additional data from a double-blind, international Phase II trial in 82 NASH patients with stage 1-3 liver fibrosis and ≥8% liver fat content showed that once-daily 3 and 6 mg subcutaneous NGM282 for 12 weeks...